The purpose of the Administration, Evaluation and Planning Core is to ensure the coordination of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer SPORE components and to provide oversight andleadership of the scientific, administrative, and fiscal aspects of the SPORE.Within the DF/HCC Lung CancerSPORE, there are several layers of oversight and evaluation. Dr. Johnson, as SPORE Director, monitorsthe progress of the Projects and Cores and oversees the Career Development Program (along with Drs.David Christian! and Daniel Tenen), the Developmental Research Program (along with Dr. DavidKwiatkowski), and all other proposed activities. Within the DF/HCC, Dr. Johnson has the authority andresources to ensure the success of this SPORE. Our Governance Committee, made up of senior membersof the DF/HCC Lung Cancer Program, meets monthly to provide immediate decision-making. Dr. Johnsonwill be joined by David Christiani, Professor of Medicine and Public Health, to assume the responsibility asCo-Pi of the SPORE. Dr. Christiani brings his leadership expertise in pulmonary medicine and public healthto our proposed studies in lung cancer. We have a strong Internal Advisory Board, comprised o f prominentmembers of the Harvard Medical School community and representing the participating institutions and majorcancer research disciplines. Our External Advisory Board will meet in the Boston area annually during thefive-year funding cycle. The membership and functions of these committees are discussed in detail in thedescription of this Core.The Administration, Evaluation and Planning Core allows for the provision ofstimulating intellectual activities, organization of venues for planning future research through seminars andretreats, and the oversight of research and spending. This Core also provides the tools to work withinstitutions inside and outside of Harvard University to leverage the considerable power of the SPORE inorder to raise more research funding for lung cancer. The responsibilities of the Administration, Evaluationand Planning Core are to: 1) Select research projects and evaluate research progress; 2) Fostercollaborative research within the SPORE and between SPOREs; 3) Integrate the Lung SPORE into theDF/HCC structure; 4) Provide necessary resources and fiscal oversight and 5) Promote rapid disseminationof significant research findings and facilitate resource exchange.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090578-06
Application #
7450282
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
6
Fiscal Year
2008
Total Cost
$194,613
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Zhou, Fei; Wang, Yanru; Liu, Hongliang et al. (2017) Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs. Mol Carcinog 56:1227-1238
Rangachari, Deepa; Costa, Daniel B (2017) Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res 6:S151-S157

Showing the most recent 10 out of 263 publications